These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 39156336)

  • 1. A Comprehensive Review on the Efficacy and Safety of Vonoprazan in the Management of Gastric Acid-Related Diseases.
    Padwale V; Kirnake V; Daswani R; Kodmalwar A; Gupta A
    Cureus; 2024 Jul; 16(7):e64777. PubMed ID: 39156336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases.
    Yang X; Li Y; Sun Y; Zhang M; Guo C; Mirza IA; Li YQ
    Dig Dis Sci; 2018 Feb; 63(2):302-311. PubMed ID: 29282636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vonoprazan Fumarate for the Treatment of Gastric Ulcers: A Short Review on Emerging Data.
    Marabotto E; Ziola S; Savarino V; Giannini EG; Furnari M; Bodini G; Zingone F; Ghisa M; Barberio B; Zentilin P; Savarino E
    Clin Exp Gastroenterol; 2020; 13():99-104. PubMed ID: 32346304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and type of adverse events in patients taking vonoprazan: A systematic review and meta-analysis.
    Xu W; Bai Z; Shang Y; Wang J; Wong Y; Qi X
    Therap Adv Gastroenterol; 2023; 16():17562848231167858. PubMed ID: 37113190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vonoprazan fumarate for the management of acid-related diseases.
    Martinucci I; Blandizzi C; Bodini G; Marabotto E; Savarino V; Marchi S; de Bortoli N; Savarino E
    Expert Opin Pharmacother; 2017 Aug; 18(11):1145-1152. PubMed ID: 28657473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of efficacy and safety of potassium-competitive acid blocker and proton pump inhibitor in gastric acid-related diseases: A systematic review and meta-analysis.
    Simadibrata DM; Syam AF; Lee YY
    J Gastroenterol Hepatol; 2022 Dec; 37(12):2217-2228. PubMed ID: 36181401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vonoprazan vs proton pump inhibitors in treating post-endoscopic submucosal dissection ulcers and preventing bleeding: A meta-analysis of randomized controlled trials and observational studies.
    Martin ; Zhou Y; Meng CX; Takagi T; Tian YS
    Medicine (Baltimore); 2020 Feb; 99(9):e19357. PubMed ID: 32118778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potassium-competitive acid blockers and acid-related disorders.
    Huang KZ; Weber HC
    Curr Opin Endocrinol Diabetes Obes; 2024 Jun; 31(3):107-114. PubMed ID: 38483115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date.
    Sugano K
    Therap Adv Gastroenterol; 2018; 11():1756283X17745776. PubMed ID: 29383028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Efficacy and Safety of Potassium-Competitive Acid Blockers vs. Proton Pump Inhibitors for Peptic Ulcer with or without
    Ouyang M; Zou S; Cheng Q; Shi X; Zhao Y; Sun M
    Pharmaceuticals (Basel); 2024 May; 17(6):. PubMed ID: 38931366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vonoprazan-associated
    Ouyang M; Zou S; Cheng Q; Shi X; Zhao Y; Sun M
    Ther Adv Drug Saf; 2024; 15():20420986241260211. PubMed ID: 39091466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vonoprazan: A New Potassium-Competitive Acid Blocker.
    St Onge E; Phillips B
    J Pharm Technol; 2023 Jun; 39(3):139-146. PubMed ID: 37323765
    [No Abstract]   [Full Text] [Related]  

  • 13. Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases.
    Inatomi N; Matsukawa J; Sakurai Y; Otake K
    Pharmacol Ther; 2016 Dec; 168():12-22. PubMed ID: 27514776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vonoprazan a novel potassium competitive acid blocker; another leap forward.
    Elsabaawy M; Shaban A; Al-Arab AE; Elbahr O; Edrees A; Afify S
    Prz Gastroenterol; 2024; 19(2):135-142. PubMed ID: 38939071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review.
    Miyazaki H; Igarashi A; Takeuchi T; Teng L; Uda A; Deguchi H; Higuchi K; Tango T
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1316-1328. PubMed ID: 30883868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vonoprazan-based therapy for
    Akazawa Y; Fukuda D; Fukuda Y
    Therap Adv Gastroenterol; 2016 Nov; 9(6):845-852. PubMed ID: 27803739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Vonoprazan for Helicobacter pylori Eradication.
    Kiyotoki S; Nishikawa J; Sakaida I
    Intern Med; 2020 Jan; 59(2):153-161. PubMed ID: 31243237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vonoprazan: A Review in Helicobacter pylori Infection.
    Shirley M
    Drugs; 2024 Mar; 84(3):319-327. PubMed ID: 38388872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438).
    Otake K; Sakurai Y; Nishida H; Fukui H; Tagawa Y; Yamasaki H; Karashima M; Otsuka K; Inatomi N
    Adv Ther; 2016 Jul; 33(7):1140-57. PubMed ID: 27287852
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.